Lobbying Filing Details

Total Spending

$530,000

Activities

3

Lobbyists

2

Gov't Entities

9

Filing Information
Filing UUID:
5ff791c9-7687-4a66-807d-011eba5b3746
Type:
Q1 - 1st Quarter - Report
Period:
2026 - 1st Quarter (Jan 1 - Mar 31)
Date Posted:
April 20, 2026 at 11:04 PM
Income:
$0
Expenses:
$530,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Jason D. Kaune, Attorney & Agent for Filer
Registrant
BIOMARIN PHARMACEUTICAL INC.

Develops and commercializes biopharmaceuticals.

San Rafael, California
Client
BIOMARIN PHARMACEUTICAL INC.
California, United States of America
Lobbying Activities (3)
Activity 1
Health Issues

GENERAL DISCUSSIONS REGARDING GENETIC TESTING AND NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION GENERAL DISCUSSIONS RELATED TO TARIFFS ON PHARMACEUTICALS GENERAL DISCUSSIONS RELATED TO METABOLIC DISORDER PUBLIC HEALTH CAMPAIGN GENERAL DISCUSSIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT

Lobbyists (2)
  • KATHRYN LOWELL
  • JOHN EDWARD GREISSING
Government Entities (5)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Commerce, Dept of (DOC)
  • Health & Human Services, Dept of (HHS)
  • Food & Drug Administration (FDA)
Activity 2
Medicare/Medicaid

GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION

Lobbyists (1)
  • JOHN EDWARD GREISSING
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING SECTION 232 INVESTIGATION ON BIOPHARMACEUTICALS

Lobbyists (1)
  • JOHN EDWARD GREISSING
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.